Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171392 | 0.98 | ACHE (0.37) | ACHEOPRK1POLBP2RX3LMNA | |
| SCHEMBL1172066 | 0.82 | ACHE (0.39) | ACHEP2RX3LMNATHRBGPR119 | |
| SCHEMBL1171253 | 0.80 | ACHE (0.37) | ACHEP2RX3LMNATHRBGPR119 | |
| SCHEMBL1171396 | 0.80 | ACHE (0.37) | ACHEP2RX3LMNATHRBGPR119 | |
| SCHEMBL1171257 | 0.78 | ACHE (0.42) | ACHELMNATHRBGPR119TP53 | |
| SCHEMBL4791331 | 0.77 | ACHE (0.40) | ACHEP2RX3LMNATHRBJAK2 | |
| SCHEMBL13356084 | 0.77 | HRH3 (0.36) | HRH3 | |
| SCHEMBL1171155 | 0.77 | HRH3 (0.36) | HRH3 | |
| SCHEMBL1171364 | 0.76 | GPR119 (0.56) | JAK2JAK1GPR119MAPT | |
| SCHEMBL1172033 | 0.74 | L3MBTL3 (0.41) | OPRK1POLBHRH3TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| WO-2007025596-A1 | PYRAZOLO [3 , 4-D] AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | ACHE 157/4885OPRK1 78/4885POLB 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.